Company Overview

CombinatoRx develops novel drug candidates with a focus on the treatment of pain and inflammation. The company applies its state-of-the-art combination drug discovery capabilities and its selective ion-channel modulation platform to generate and advance innovative therapeutics with the goal of establishing revenue generating collaborations in a variety of therapeutic areas.

Focusing in core therapeutic areas of pain and inflammation

At CombinatoRx, we are creating innovative product candidates for the treatment of pain and inflammation and have focused our portfolio and research and development efforts in these core therapeutic areas.

Leveraging our expertise and pipeline to develop innovative product candidates

As a result of our driving mission to become a successful pain and inflammation company, we have prioritized our product candidate pipeline and proven drug development and regulatory expertise to focus our time and resources on advancing those internal programs that best fit that profile.

Revenue generating collaborations to fund internal R&D efforts

• Pain: Exalgo™, exclusively marketed by Covidien.
• Ophthalmology: Prednisporin exclusively licensed to Fovea/Sanofi-Aventis
• Oncology: Novartis strategic research alliance

Applying our state-of-the-art drug discovery technologies to fuel our pipeline and generate revenue

• cHTS synergistic combination high throughput screening platform
• Selective Ion channel modulation platform

CombinatoRx Products